Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease

RT @nvillain_alz: (14/25) Let's try to sum up delayed-start designs simply: all patients will end up with a treatment, but some will start…

RT @nvillain_alz: (14/25) Let's try to sum up delayed-start designs simply: all patients will end up with a treatment, but some will start…

(14/25) Let's try to sum up delayed-start designs simply: all patients will end up with a treatment, but some will start with a placebo (delayed start) while others will directly start with the active treatment (early start). https://t.co/CQYogCrwUJ https

@MadhavThambiset @VincentPlanche @smead2 @ProfRobHoward @kathy_y_liu 8/x Sources: https://t.co/CQYogCrwUJ https://t.co/lZzDYrY6f4 https://t.co/nEJFf80oYF